Garland Surgical develops the TriActiv Hip, a patented triaxial hip system designed to deliver a wider, more natural range of motion with enhanced stability and ultra-low wear compared to conventional ball-and-socket implants. The company positions TriActiv to address instability and longevity concerns for higher-risk and high-demand patients and to compete in an estimated $8 billion total hip replacement market. Garland aims to complete final design verification, pursue regulatory submissions for FDA and MDR clearance, and progress to first-in-human clinical studies as part of its evidence-generation roadmap. The business is supported by a recently closed €3.5 million seed round and is preparing a staged Series A with advisory support from Ferghana Partners to fund regulatory and clinical milestones and enable early commercialization. Founded in 2022, Garland is headquartered near Worcester, United Kingdom, and operates in Malta with collaborations across Europe.

Total raised

$4M

Funding rounds

2

Latest round

Seed

Latest activity

May 2026